Sumanirole

Sumanirole

Clinical data
Other names	PNU-95,666
ATC code	none
Identifiers
IUPAC name (R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one
CAS Number	179386-43-7 179386-44-8 (maleate)
PubChem CID	9818479
IUPHAR/BPS	3949
ChemSpider	7994229
UNII	3E93IV1U45
ChEMBL	ChEMBL419792
Chemical and physical data
Formula	C11H13N3O
Molar mass	203.245 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23

Sumanirole (PNU-95,666) is a highly selective D₂ receptor full agonist, the first of its kind to be discovered. It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D₂-linked (vs. D₁-, D₃-, D₄-, and D₅-linked) mechanism of action.

In 2004, Pfizer announced the end of their clinical development program for sumanirole, citing “recent studies that failed to sufficiently distinguish sumanirole from currently available therapies”.

See also

• Ropinirole